Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
After a staggering multi-year rally, shares of American Superconductor (AMSC) are showing signs of cooling momentum. With a sky-high P/E ratio and a significant gap between its current price and analyst fair value estimates, investors are grappling with a critical question: is this a buying opportunity or a signal to take profits?
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
A surprise announcement from Google DeepMind triggered a sector-wide sell-off, hitting mobile gaming and ad-tech stocks. Analysts debate the long-term implications for companies like AppLovin.
Congress has approved $23 billion in initial funding for the ambitious Golden Dome missile defense initiative, yet the absence of a detailed spending blueprint from the Pentagon is stalling progress and clouding investment prospects for 2026.
From post-IPO darling to a stock trading near historic lows, Rivian faces a critical five-year window. With new models on the horizon and a major Volkswagen partnership, analysts see a path to growth—if it can navigate fierce competition and persistent losses.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
A patent lawsuit filed by Solos Technology against Meta Platforms, Oakley, and EssilorLuxottica targets core smart glasses technology, posing significant risks to Meta's wearables strategy and valuation.
Amidst economic crosscurrents, a closer look at Ideal Power, NetSol Technologies, and Sono-Tek reveals companies executing distinct strategies to navigate growth and profitability challenges in the high-risk, high-reward penny stock arena.
MKS Instruments' recent €1 billion debt offering to refinance its balance sheet arrives as its stock rides a powerful rally, forcing investors to weigh strong operational momentum against a valuation that appears stretched.
BHP Group achieves a key milestone with full autonomy at its Escondida Norte copper pit, boosting safety and efficiency for its strategic copper expansion. Meanwhile, the miner contends with the commercial impact of China's ongoing ban on iron ore from its Jimblebar operation, forcing a reshuffle of global sales channels.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
IonQ's acquisition of semiconductor foundry SkyWater Technology marks a pivotal shift, granting it a unique edge in chip manufacturing and positioning it as a frontrunner for lucrative government contracts in the nascent quantum computing race.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
The automotive safety giant posted historic sales and cash flow in 2025, powered by explosive growth with Chinese automakers and in India. While navigating a softer production forecast and tariff headwinds, management projects margin expansion for 2026.
Allegro MicroSystems (ALGM) has restructured its credit facilities, securing $285 million in new term loans maturing in 2030. The move provides the semiconductor firm with fresh capital for corporate initiatives as it navigates a capital-intensive sector while maintaining a premium market valuation.
Wall Street analysts have updated their price target for Amcor (NYSE: AMCR), prompting a fresh look at the investment case for the global packaging leader. The revision reflects evolving views on the company's strategic positioning and market dynamics.
RBC Capital initiates coverage on Marvell Technology with an 'Outperform' rating, highlighting the chipmaker's strategic positioning in data center and custom AI silicon as key growth drivers.
